Take a minute to write an introduction that is short, sweet, and to the point.

It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

We develop transformative therapies for rare kidney diseases

At DETERA Therapeutics, we are dedicated to developing transformative therapies for rare kidney diseases in both adults and children. Our focus is on conditions with urgent therapeutic needs and significant unmet medical challenges, despite established patient management protocols.

We aim to become a leading innovator in the rare kidney disease market. Our initial priority is addressing Crescentic Glomerulonephritis, a condition marked by severe treatment gaps and high healthcare costs. Future indications will follow as part of our long-term strategy. Our flagship program, DTR8, stems from over 15 years of pioneering research conducted at Inserm and CEA.

Supported by high-impact publications in international journals and scientific awards, DTR8 is a preclinical compound designed to preserve kidney structure and function in the face of disease progression. This disease-modifying orphan drug addresses a critical unmet need.